Copyright © 2021. Inderes Oyj. All rights reserved.

CellaVision

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
21.1.
2022

CellaVision AB (publ) will publish the Year-end bulletin for 2021, on February 4, 2022 at 7:20 CET

The report will be available at www.cellavision.com

In connection with the release of the year-end bulletin analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Simon Østergaard, President & CEO, will present and comment the report.

Tiedotteet
13.1.
2022

CellaVision’s Chief Financial Officer (CFO), Magnus Blixt has informed that he will leave his position as CFO of CellaVision, to take on the position as CEO of the medical technology company Dignitana AB. Magnus will continue to support CellaVision until mid-April 2022.

Muut analyysit
22.10.
2021

Redeyes's first comments on the Q3 report earlier this morning.

Tiedotteet
22.10.
2021

1 July-30 September 2021

  • Net sales increased by 50% to SEK 132 million (88).
  • Sales increased organically by 52% (-24), currency effect -2%
  • EBITDA amounted to SEK 42 million (25).
  • EBITDA margin amounted to 32% (28).
  • Profit before tax amounted to SEK 33 million (16).
  • Earnings per share before and after dilution were SEK 1.09 (0.56).
  • Cash flow from operating activities amounted to SEK 49 million (-4).


Tiedotteet
8.10.
2021

CellaVision AB (publ) will publish the Interim report for the third quarter, on October 22, 2021 at 7:20 CEST. The report will be available at www.cellavision.com

In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CEST where
Simon Østergaard, President & CEO, will present and comment the report.

Muut analyysit
20.7.
2021

Redeye views the Q2 from Cellavision this morning as very much in line with our expectations and continued solid recovery story.

Tiedotteet
20.7.
2021

1 April-30 June 2021

  • Net sales increased by 15% to SEK 135.5 million (118.0).
  • Sales increased organically by 23% (-15), currency effect -8%.
  • EBITDA amounted to SEK 47.1 million (36.2).
  • EBITDA margin amounted to 35% (31).
  • Profit before tax amounted to SEK 38.9 million (34.4).
  • Earnings per share before and after dilution were SEK 1.30 (1.14).
  • Cash flow from operating activities amounted to SEK 38.9 million (34.1).


1 January-30 June 2021

Tiedotteet
5.7.
2021

CellaVision AB (publ) will publish the Interim report for the second quarter, on July 20, 2021 at 7:20 CEST.

The report will be available at www.cellavision.com

In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CEST where
Simon Østergaard, President & CEO, will present and comment the report.

Tiedotteet
29.4.
2021

The following resolutions were passed at the annual general meeting (the “AGM”) of CellaVision AB (publ) (“CellaVision”) on 29 April 2021. Due to the covid-19 pandemic, CellaVision‘s annual general meeting was carried out through advance voting (postal voting) only.

Muut analyysit
28.4.
2021

Redeye’s first comments on CellaVision’s report for Q1’21. The report showed stronger sales than we expected at SEK 134m vs. our SEK 123m, a flat development compared to last year.

CellaVision